Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib [0.03%]
索拉非尼治疗具有KIT Val560Asp突变的IV期肛门黏膜黑色素瘤的完全反应
Alfonso Quintás-Cardama,Alexander J Lazar,Scott E Woodman et al.
Alfonso Quintás-Cardama et al.
Background: A 79-year-old man presented to his primary care physician with a 2-month history of pruritus ani and a pigmented nodular lesion was discovered in the posterior rectum. The patient had no other symptoms, or any...
Is intravenous iron supplementation with erythropoiesis-stimulating agents beneficial in cancer patients with anemia? [0.03%]
癌症患者的贫血需要刺激红细胞生成的药物与静脉铁剂治疗吗？
Julia Bohlius
Julia Bohlius
Chemotherapy-induced anemia is often an important problem for cancer patients, and this complication can be treated with erythropoiesis-stimulating agents (ESAs). This commentary discusses the findings of a study by Bastit et al., in which ...
The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy [0.03%]
靶向治疗时代的肾细胞癌去瘤肾切除术的作用
Simon Chowdhury,Peter G Harper,Toni K Choueiri
Simon Chowdhury
Thomas S Deisboeck,Le Zhang,Jeongah Yoon et al.
Thomas S Deisboeck et al.
At the dawn of the era of personalized, systems-driven medicine, computational or in silico modeling and the simulation of disease processes is becoming increasingly important for hypothesis generation and data integration in both experimen...
Anal cancer: is neoadjuvant cisplatin chemotherapy or chemoradiotherapy friend or foe? [0.03%]
肛癌：新辅助顺铂化疗或化学放疗是敌是友？
Robert Glynne-Jones,Suzannah Mawdsley
Robert Glynne-Jones
This Practice Point commentary discusses the findings of the Intergroup RTOG 98-11 trial, which aimed to investigate both the potential role of cisplatin as neoadjuvant chemotherapy, and also its role concurrently in combination with radiot...
Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma [0.03%]
抗原特异性CD4+t细胞过继传输治疗转移性黑色素瘤
F Stephen Hodi,David E Fisher
F Stephen Hodi
Clinical investigations of adoptive therapy in solid tumors have primarily focused on CD8(+) cells. A study by Hunder et al. is the first to demonstrate the significance of antigen-specific CD4(+) T cells. An in vitro method was used to tre...
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas [0.03%]
组蛋白去乙酰酶抑制剂治疗皮肤T细胞淋巴瘤的进展及前景展望
Omar Khan,Nicholas B La Thangue
Omar Khan
Reversible acetylation is mediated by histone deacetylase (HDAC), which is involved in regulating a broad repertoire of physiological processes, many of which are under aberrant control in tumor cells. Inhibition of HDAC activity prompts tu...
Technology Insight: Combined external-beam radiation therapy and brachytherapy in the management of prostate cancer [0.03%]
技术聚焦：体外放射治疗与组织内近距离放疗联合用于前列腺癌的治疗
Mark D Hurwitz
Mark D Hurwitz
External-beam radiation therapy (EBRT) combined with brachytherapy is an attractive treatment option for selected patients with clinically localized prostate cancer. This therapeutic strategy offers dosimetric coverage if local-regional mic...
Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck [0.03%]
凯昔明单抗治疗复发性和转移性头颈部鳞状细胞癌的用药见解
Jacques Bernier
Jacques Bernier
Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) have a poor prognosis, particularly those whose disease has progressed on previous platinum-containing therapy. The epidermal growth factor recep...
Alberto Costa,Vittorio Zanini
Alberto Costa
The management of precancerous lesions of the breast has become a considerable clinical problem in the past 20 years, mostly as a consequence of increased detection due to the introduction of mammographic screening. It is not possible to id...